Philippe Agape
16 Papers
107 Citations
Philippe Agape is an academic researcher. The author has contributed to research in topics: Medicine & Dasatinib. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot,Aude Charbonnier,Pascale Cony-Makhoul,Philippe Agape,Franck E. Nicolini,Bruno Varet,Martine Gardembas,Gabriel Etienne,Delphine Rea,Lydia Roy,Martine Escoffre-Barbe,Agnès Guerci-Bresler,Michel Tulliez,Stéphane Prost,Marc Spentchian,Jean Michel Cayuela,Josy Reiffers,Jean-Claude Chomel,Ali G. Turhan,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +21 more
TL;DR: Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.
404
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot,marie Magdelaine Coude,Nicola Gökbuget,Carlo Gambacorti Passerini,Sandrine Hayette,Jean-Michel Cayuela,Françoise Huguet,Thibaut Leguay,Patrice Chevallier,Celia Salanoubat,Caroline Bonmati,Magda Alexis,Mathilde Hunault,Sylvie Glaisner,Philippe Agape,Christian Berthou,Eric Jourdan,José Fernandes,Laurent Sutton,Anne Banos,Oumedaly Reman,Bruno Lioure,Xavier Thomas,Norbert Ifrah,Marina Lafage-Pochitaloff,Anne Bornand,Laure Morisset,Valérie Robin,Heike Pfeifer,André Delannoy,Josep M. Ribera,Renato Bassan,Marc Delord,Dieter Hoelzer,Hervé Dombret,Oliver G. Ottmann +35 more
TL;DR: Dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL and monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy.
286
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance
Philippe Rousselot,Jean Michel Cayuela,Sandrine Hayette,Christian Recher,Thibaut Leguay,Celia Salanoubat,Francis Witz,Magda Alexis,Mathilde Hunault,Maud Janvier,Philippe Agape,Christian Berthou,Eric Jourdan,José Fernandes,Laurent Sutton,Anne Banos,Oumedaly Reman,Bruno Lioure,Xavier Thomas,Norbert Ifrah,Nicola Gökbuget,Dieter Hoelzer,André Delannoy,Renato Bassan,José M. Ribera,Sebastian Giebel,Hervé Dombret,Oliver G. Ottmann +27 more
TL;DR: Cytogenetics findings at diagnosis were good predictors for RFS: the median RFS for patients with isolated Ph was not reached while it was 19.2 months in patients with additional cytogenetic abnormalities, and T315I ASO RTQ-PCR analysis during follow-up was predictive for relapse.
33
Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Nathalie Dhedin,Anne Krivine,Nicole Le Corre,Nicole Le Corre,Alain Mallet,Bruno Lioure,Jacques-Olivier Bay,Marie-Thérèse Rubio,Philippe Agape,Anne Thiebaut,Jérôme Le Goff,Brigitte Autran,Brigitte Autran,Patricia Ribaud +13 more
TL;DR: In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.
31
Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))
Philippe Rousselot,Jean-Michel Cayuela,Christian Recher,Thibaut Leguay,Celia Salanoubat,Francis Witz,Magda Alexis,Maud Janvier,Mathilde Hunault,Philippe Agape,Christian Berthou,Eric Jourdan,José Fernandes,Laurent Sutton,Anne Banos,Oumedaly Reman,Bruno Lioure,Nicola Gökbuget,Dieter Hoelzer,André Delannoy,Renato Bassan,José-María Ribera,Sebastian Giebel,Sandrine Hayette,Oliver G. Ottmann,Hervé Dombret +25 more
TL;DR: The rate of complete molecular remission (CMR) after induction was 33% in blood and 28% in bone marrow and MRD level continued to decrease with time, and second-generation TKI may have a place in the management of patients with Ph-positive ALL.
27